Winan van Houdt: Neo-Adjuvant Chemotherapy in Retroperitoneal Sarcoma and STRASS2 Trial Update at SSO Annual Meeting
Winan van Houdt, Surgical Oncologist at Antoni van Leeuwenhoek/the Netherlands Cancer Institute, shared a post on Linkedin:
“Was good to be at the annual meeting of the Society of Surgical Oncology in Tampa to discuss the role of neo-adjuvant chemotherapy in retroperitoneal sarcoma from real world data, as well as giving an update on our STRASS2 trial from EORTC – European Organisation for Research and Treatment of Cancer at the TARPSWG meeting.
Also discussing discussing the surgical stance on the impact of neo-adjuvant checkpoint inhibition for stage 3 melanoma at the international neo-adjuvant melanoma consortium meeting, as well as the surgical role and vision on TIL therapy in the newly formed international surgical TIL collaboration.
And finally meeting our international friends and colleagues form the surgical oncology, sarcoma and melanoma field. What an inspiration to work together so we can all in our own hospitals continue to help our patients and improving care for them.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023